GleamWall
中文EN

LAB STANDARD BIOTOOLS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1162194 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.2%
TTM net income YoY203.8%
TTM EPS YoY203.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin52.2%
Operating margin-97.5%
Net margin157.6%
FCF margin-77.8%
EBITDA margin-91.3%

Returns

ROE27.9%
ROA22.7%
ROIC (approx.)-23.4%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets12.5%
Debt / equity0.00x
Current ratio9.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.48x
Accruals ratio33.6%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$19.39M$20.10M$21.15M$23.80M$19.55M$21.76M$20.22M$24.78M
Cost of revenue$8.56M$9.57M$9.84M$12.41M$10.07M$11.13M$9.17M$13.42M
Gross profit$10.83M$10.54M$11.31M$11.38M$9.48M$10.63M$11.05M$11.36M
R&D expense$2.08M$1.98M$2.12M$7.97M$6.36M$6.22M$5.44M$7.04M
SG&A expense$16.84M$16.39M$18.61M$25.34M$26.59M$28.11M$29.82M$27.32M
Operating income-$19.77M-$25.39M-$12.50M-$24.64M-$32.94M-$25.70M-$26.97M-$26.08M
Pretax income-$14.95M-$21.43M-$14.62M-$22.03M-$32.90M-$18.28M-$23.49M-$26.90M
Income tax$27,000$90,000$11,000-$35.93M-$1.22M-$609,000-$119,000$272,000
Net income$13.48M-$26.76M$127.07M$19.28M-$34.69M-$33.46M-$26.03M-$34.07M
EBITDA-$18.57M-$24.11M-$11.09M-$23.35M-$31.44M-$23.70M-$23.70M-$22.94M
EPS (basic)0.03-0.070.33—-0.09-0.09-0.07—
EPS (diluted)0.03-0.070.33—-0.09-0.09-0.07—
Weighted avg. shares (diluted)393.56M390.88M388.20M—382.63M380.50M378.23M—
Balance sheet
Cash & equivalents$267.49M$270.03M$265.77M$120.86M$132.01M$161.20M$153.47M$168.82M
Short-term investments$193.62M$206.69M$189.40M$66.71M$65.48M$78.47M$107.18M$126.15M
Receivables$12.98M$15.75M$16.64M$13.43M$13.54M$14.61M$35.48M$14.74M
Inventory$17.62M$17.10M$18.59M$19.98M$25.42M$24.17M$42.12M$20.74M
Current assets$497.30M$516.87M$521.45M$454.26M$472.44M$506.04M$344.02M$375.88M
PP&E, net$13.24M$15.30M$17.10M$19.27M$20.74M$22.68M$43.59M$22.77M
Goodwill——————$111.72M$111.30M
Intangibles——————$28.06M$28.95M
Total assets$635.33M$627.22M$639.11M$567.75M$539.64M$556.97M$579.60M$612.35M
Current liabilities$51.02M$56.80M$42.20M$108.31M$107.97M$98.02M$56.24M$65.89M
Long-term debt———————$299,000
Total debt———————$299,000
Total liabilities$79.58M$87.25M$77.99M$143.46M$139.98M$132.43M$125.00M$140.62M
Shareholders' equity$555.75M$539.97M$561.12M$424.29M$399.66M$424.54M$454.60M$471.72M
Net debt———————-$168.52M
Shares outstanding394.67M392.12M390.14M386.38M383.61M381.69M379.09M377.53M
Cash flow statement
Operating cash flow-$6.16M-$10.31M-$46.60M-$1.19M-$22.20M-$20.67M-$30.28M-$14.06M
Capital expenditure$0$344,000$570,000$476,000$886,000$1.89M$5.05M$3.38M
Free cash flow-$6.16M-$10.65M-$47.17M-$1.67M-$23.09M-$22.55M-$35.34M-$17.44M
Investing cash flow$4.83M$14.41M$191.09M-$8.04M-$6.68M$27.50M$14.62M$25.73M
Financing cash flow-$598,000-$138,000-$40,000$620,000-$112,000$108,000-$46,000-$54.52M
Depreciation & amortization$1.20M$1.27M$1.41M$1.29M$1.50M$2.00M$3.27M$3.14M
Stock-based compensation$3.72M$4.05M$8.82M$5.74M$7.54M$5.37M$9.01M$7.47M
Share buybacks———$0$0$0$0$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.